BioCardia annual operating margin
2011
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
BioCardia's operating margin was −13,794.83% for fiscal 2024.
View full BioCardia company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2024 | 2024-12-31 | −13,794.83% | −11353.74 pp |
| 2023 | 2023-12-31 | −2,441.09% | −1560.84 pp |
| 2022 | 2022-12-31 | −880.25% | +364.08 pp |
| 2021 | 2021-12-31 | −1,244.33% | +9465.32 pp |
| 2020 | 2020-12-31 | −10,709.66% | −8707.82 pp |
| 2019 | 2019-12-31 | −2,001.83% | +254.49 pp |
| 2018 | 2018-12-31 | −2,256.32% | +333.45 pp |
| 2017 | 2017-12-31 | −2,589.77% | −1268.94 pp |
| 2016 | 2016-12-31 | −1,320.83% | −722.49 pp |
| 2015 | 2015-12-31 | −598.34% | +4551.66 pp |
| 2011 | 2011-12-31 | −5,150.00% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2024 | 2024-06-30 | −54,966.67% | −46938.76 pp |
| Q1 2024 | 2024-03-31 | −4,136.36% | +1348.01 pp |
| Q4 2023 | 2023-12-31 | −16,030.77% | −13183.60 pp |
| Q3 2023 | 2023-09-30 | −727.73% | +715.67 pp |
| Q2 2023 | 2023-06-30 | −8,027.91% | −7771.64 pp |
| Q1 2023 | 2023-03-31 | −5,484.38% | +60.63 pp |
| Q4 2022 | 2022-12-31 | −2,847.17% | +1533.84 pp |
| Q3 2022 | 2022-09-30 | −1,443.40% | −1113.55 pp |
| Q2 2022 | 2022-06-30 | −256.26% | +4800.26 pp |
| Q1 2022 | 2022-03-31 | −5,545.00% | +915.87 pp |
| Q4 2021 | 2021-12-31 | −4,381.01% | +3223.34 pp |
| Q3 2021 | 2021-09-30 | −329.84% | +10987.81 pp |
| Q2 2021 | 2021-06-30 | −5,056.52% | +8180.52 pp |
| Q1 2021 | 2021-03-31 | −6,460.87% | +5668.08 pp |
| Q4 2020 | 2020-12-31 | −7,604.35% | −5951.54 pp |
| Q3 2020 | 2020-09-30 | −11,317.65% | −9654.24 pp |
| Q2 2020 | 2020-06-30 | −13,237.04% | −8862.62 pp |
| Q1 2020 | 2020-03-31 | −12,128.95% | −10422.00 pp |
| Q4 2019 | 2019-12-31 | −1,652.80% | +1900.59 pp |
| Q3 2019 | 2019-09-30 | −1,663.40% | +2586.60 pp |
| Q2 2019 | 2019-06-30 | −4,374.42% | −3013.75 pp |
| Q1 2019 | 2019-03-31 | −1,706.94% | +112.15 pp |
| Q4 2018 | 2018-12-31 | −3,553.40% | −30.40 pp |
| Q3 2018 | 2018-09-30 | −4,250.00% | −1912.31 pp |
| Q2 2018 | 2018-06-30 | −1,360.67% | +1289.33 pp |
| Q1 2018 | 2018-03-31 | −1,819.10% | +279.44 pp |
| Q4 2017 | 2017-12-31 | −3,523.00% | −988.69 pp |
| Q3 2017 | 2017-09-30 | −2,337.69% | −900.09 pp |
| Q2 2017 | 2017-06-30 | −2,650.00% | −1693.06 pp |
| Q1 2017 | 2017-03-31 | −2,098.54% | −1494.05 pp |
| Q4 2016 | 2016-12-31 | −2,534.31% | −2097.46 pp |
| Q3 2016 | 2016-09-30 | −1,437.61% | −661.14 pp |
| Q2 2016 | 2016-06-30 | −956.94% | −429.67 pp |
| Q1 2016 | 2016-03-31 | −604.49% | +712.17 pp |
| Q3 2012 | 2012-09-30 | −436.84% | — |
| Q2 2012 | 2012-06-30 | −776.47% | — |
| Q1 2012 | 2012-03-31 | −527.27% | — |
| Q4 2011 | 2011-12-31 | −1,316.67% | — |
Over the last five reported fiscal years, BioCardia's operating margin decreased from −2,001.83% to −13,794.83%, a change of −11793.00 percentage points. The latest reported quarter, Q2 2024, shows −54,966.67%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BioCardia filings at SEC.gov ↗